Pathogenesis of epidermolysis bullosa acquisita

Ralf J. Ludwig; Detlef Zillikens

doi:10.1016/j.det.2011.03.003

Pathogenesis of epidermolysis bullosa acquisita

Ralf J. Ludwig^*, Detlef Zillikens

^*Corresponding author for this work

Department of Dermatology, Allergology and Venereology

29 Citations (Scopus)

Abstract

Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal. However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA. Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.

Original language	English
Journal	Dermatologic Clinics
Volume	29
Issue number	3
Pages (from-to)	493-501
Number of pages	9
ISSN	0733-8635
DOIs	https://doi.org/10.1016/j.det.2011.03.003
Publication status	Published - 01.07.2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.det.2011.03.003

Cite this

@article{ee0f8257753a4dc1b6fffe10c48ae008,

title = "Pathogenesis of epidermolysis bullosa acquisita",

abstract = "Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal. However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA. Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.",

author = "Ludwig, \{Ralf J.\} and Detlef Zillikens",

year = "2011",

month = jul,

day = "1",

doi = "10.1016/j.det.2011.03.003",

language = "English",

volume = "29",

pages = "493--501",

journal = "Dermatologic Clinics",

issn = "0733-8635",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Pathogenesis of epidermolysis bullosa acquisita

AU - Ludwig, Ralf J.

AU - Zillikens, Detlef

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal. However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA. Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.

AB - Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease characterized by autoantibodies to type VII collagen. Clinically, a noninflammatory and an inflammatory variant of EBA can be distinguished. Despite major achievements in the understanding of EBA, current therapeutic options are far from optimal. However, with an emerging and more detailed understanding of the events ultimately leading to blister formation in EBA, novel therapeutic options may become available for patients with EBA. Therefore, this article reviews the current understanding of the pathogenesis of EBA and may indicate possible avenues towards a more targeted therapy for EBA and possibly other antibody-mediated autoimmune diseases.

UR - https://www.scopus.com/pages/publications/79956283478

U2 - 10.1016/j.det.2011.03.003

DO - 10.1016/j.det.2011.03.003

M3 - Scientific review articles

C2 - 21605817

AN - SCOPUS:79956283478

SN - 0733-8635

VL - 29

SP - 493

EP - 501

JO - Dermatologic Clinics

JF - Dermatologic Clinics

IS - 3

ER -

Pathogenesis of epidermolysis bullosa acquisita

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this